Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jose Esquenazi

Nephrology Miami, FL Medical Doctor

NPI 1154522852 CMS profile 279705

7900 S.W. 57 Avenue #21, Miami, FL 33143

Open in the dashboard

General payments

$7,118

285 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jose Esquenazi of Miami, FL is reported in the CMS Open Payments database as having received $7,118 across 285 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,637 65
2024 General $1,586 60
2023 General $1,200 49
2022 General $665 25
2021 General $334 15
2020 General $490 26
2019 General $1,205 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Esquenazi
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Jose Esquenazi were reported at $1,637. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Jose Esquenazi Nephrology median Middle half National median
2019 $1,205 $236 $90–$588 $163
2020 $490 $135 $46–$364 $114
2021 $334 $202 $67–$551 $132
2022 $665 $242 $77–$695 $149
2023 $1,200 $254 $84–$766 $160
2024 $1,586 $300 $99–$852 $164
2025 $1,637 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,088 39 payments
  2. Relypsa, Inc. $676 32 payments
  3. Otsuka America Pharmaceutical, Inc. $564 24 payments
  4. Mallinckrodt Hospital Products Inc. $534 22 payments
  5. Amgen Inc. $520 19 payments
  6. Calliditas Therapeutics US Inc. $459 14 payments
  7. Aurinia Pharma U.S., Inc. $379 15 payments
  8. GlaxoSmithKline, LLC. $352 11 payments
  9. Novartis Pharmaceuticals Corporation $335 16 payments
  10. Retrophin, Inc. $262 11 payments
  11. Other $1,949 82 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,870 279 payments
  2. Education $248 6 payments
Products named General payments · program years 2019–2025
  1. LOKELMA $658 19 payments
  2. ACTHAR $505 21 payments
  3. TARPEYO $411 12 payments
  4. JYNARQUE $409 16 payments
  5. LUPKYNIS $379 15 payments
  6. BENLYSTA $329 10 payments
  7. Veltassa Hyperkalemia $323 17 payments
  8. Veltassa Hyperkalemia $322 13 payments
  9. IBSRELA $241 12 payments
  10. KRYSTEXXA $200 4 payments
  11. Other $2,728 117 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,168

Median for Internal Medicine: 777

Drug cost

$576,760

Median for Internal Medicine: $73,373

Branded share of claims

50.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lokelma Sodium Zirconium Cyclosilicate Brand 171 $158,284
Velphoro Sucroferric Oxyhydroxide Brand 70 $157,686
Veltassa Patiromer Calcium Sorbitex Brand 119 $137,759
Farxiga Dapagliflozin Propanediol Brand 70 $70,515
Auryxia Ferric Citrate Brand 15 $20,493
Kerendia Finerenone Brand 11 $13,856
Sevelamer Carbonate Generic 58 $8,551
Nifedipine Er Nifedipine Brand 103 $3,174
Potassium Citrate Er Potassium Citrate Brand 12 $961
Losartan Potassium Generic 114 $875

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$216,856

Medicare's payments for the services billed

Medicare patients

668

Average age 76

Services billed

2,063

305 women, 363 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Ischemic heart disease 67%
Diabetes 65%
Heart failure 55%
Arthritis 55%
Atrial fibrillation 46%
Depression 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
  • Amgen Inc. $200
$200 — —
TARPEYO
  • CALLIDITAS THERAPEUTICS US INC. $199
$199 — —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $144
$144 — —
LUPKYNIS
  • Aurinia Pharma U.S., Inc. $106
$106 — —
JYNARQUE
  • Otsuka America Pharmaceutical, Inc. $103
$103 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

285 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record